预约演示

Galapagos halts lupus CAR-T program, confirms 100 layoffs so far this year

2024-02-23

临床2期ASH会议细胞疗法免疫疗法

The release was light on details for the move, with Galapagos only ascribing the pipeline change to “strategic reasons.”

Galapagos has never been afraid of reworking its pipGalapagosworkforce to face the future. 2022 saw the Belgian biotech pivot to CAR-T therapies and then drop its kidney disease and fibrosis programs—the latter move coinciding with laying off 200 employees.

Galapagost year was less disruptive for Galapagos, it appears the pace of change has ramped back up in 2024. In its full-year earnings report, the company revealedkidney diseaselayoffibrosisd at back in October as a way to “streamline” operations have now taken place.

These roles were culled from “across theGalapagoss organization” since the start of the year and were aimed at aligning with “Galapagos’ renewed focus on innovation,” the company said.

Galapagos also used the earnings report tGalapagose that it has decided to halt work on its CD19 CAR-T candidate aimed at refrGalapagosstemic lupus erythematosus. The release was light on details for the move, with Galapagos only ascribing the pipeline change to “strategic reasons.”

Galapagosovember, Galapagos reported that “further progress” had been made in preparing to lCD19h a phase 1b study of the refractory systemic lupus erythematosusents with refractory systemic lupus erythematosus. ButGalapagosve been no updates since.

The biotech has alGalapagosesting GLPG5101 in patients with relapsed/refractory non-Hodgkin lymphoma. The company shared early data from phase 1GLPG5101rials of the CAR-T refractory systemic lupus erythematosuscan Society of Hematology general meeting in December, claiming the “encouraging safety profile” and initial efficacy data showed “the potential of our CAR-T pipeline beyond these initial indications.”

GLPG5101 isn’t the only candidate GLPG5101s was testing in srelapsed/refractory non-Hodgkin lymphomae company has a selective tyrosine kinase inhibitor called GLPG3667 in a phase 2 trial for the autoimmune condition.

GLPG5101e, the company has expandeGalapagosit this year, kisystemic lupus erythematosusllion upfront deal to use BridGene Biostyrosine kinaseroteomics platformGLPG3667over new small molecules for cancer. When announcing in October that the once-promising JAK inhibitor Jyseleca would be transferred to Italy’s Alfasigma, Galapagos suggested that on top of the roughly 400 employees that would move with the drug, another 100 positions would be trimmed at some point.

The company still has plenty of money at hand. Galapagos entered the new year with 3.7 billion euros ($4 billion)BridGene Biosciencesial Officer and Chief Operating Officer Thad Huston described icancererday’s earnings release as “a strong financial positJAK inhibitor JAK.”Jyseleca Alfasigma Galapagos

“We will continue to execute on business develoGalapagosortunities and invest in our pipeline to drive value for all our stakeholders,” Huston added.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构